Four Accused By UK's CMA On Nortriptyline
King Pharmaceuticals and Auden Mckenzie have been accused by the UK’s competition regulator of sharing out the supply of nortriptyline 10mg and 25mg tablets, in a case that also implicates Alissa and Lexon for exchanging commercially-sensitive information as part of an effort to drive up prices.
You may also be interested in...
Four firms – Accord, Alissa, Lexon and King – have been fined by the UK’s Competition and Markets Authority over price-fixing and information-sharing activities related to the supply of nortriptyline.
Alissa Healthcare and King Pharmaceuticals have admitted colluding over UK supplies of nortriptyline to keep prices up, following an investigation launched by the country’s CMA.
The BGMA has condemned anti-competitive behavior in the UK after Aspen paid the NHS £8m in a landmark case over “illegal market sharing”.